Rapamycin response in tumorigenic and non-tumorigenic hepatic cell lines.
The mTOR inhibitor rapamycin has anti-tumor activity across a variety of human cancers, including hepatocellular carcinoma. However, resistance to its growth inhibitory effects is common. We hypothesized that hepatic cell lines with varying rapamycin responsiveness would show common characteristics...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2009-10-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC2756589?pdf=render |